PAVmed (PAVM) Common Equity (2015 - 2025)

PAVmed's Common Equity history runs 11 years deep, the most recent figure standing at $34.0 million for Q4 2025.

• On a quarterly basis, Common Equity rose 582.97% year-over-year to $34.0 million in Q4 2025; TTM through Dec 2025 was $34.0 million, a 582.97% increase from a year earlier, with the FY2025 full-year figure at $34.0 million, up 582.97% from the prior year.
• Common Equity advanced to $34.0 million in Q4 2025 per PAVM's latest filing, from $32.5 million in the prior quarter.
• Across five years, Common Equity topped out at $79.4 million in Q4 2021 and bottomed at -$24.0 million in Q4 2023.
• The 5-year median for Common Equity is $28.4 million (2022), against an average of $20.8 million.
• Across the five-year window, Common Equity surged 16890.27% in 2021 and plunged 2146.02% in 2024, its largest moves.
• Year by year, Common Equity stood at $79.4 million in 2021, then tumbled by 86.23% to $10.9 million in 2022, then plunged by 319.66% to -$24.0 million in 2023, then surged by 70.72% to -$7.0 million in 2024, then surged by 582.97% to $34.0 million in 2025.
• Per Business Quant, the three latest PAVM Common Equity figures stand at $34.0 million (Q4 2025), $32.5 million (Q3 2025), and $28.2 million (Q2 2025).